Home
About Us
Overview
Culture
Team
Drug R & D
Fields
Indications
Pipeline
Technology Platform
Biotechnology Platform
Chemistry Service
News Center
Company News
Industry News
Join Us
Team Building
Career Development
Contact Us
Xingmin Zhang MD, Ph.D.
Details
→
BroadenBio’s HPK1 Inhibitor Selected for Poster Presentation in AACR 2023
BroadenBio Announces First Patient Dosed in Phase 1 Study of BB102 in China
BB102 Received FDA Approval for Clinical Trials in Patients with Advanced Solid Tumors
BB102 Approved for Clinical Trials in Patients with Advanced Solid Tumors
BroadenBio Completed PreA+ Round of Financing, Building Immunology and Small Molecule Coupling Technology Platform